Epirubicin - CAS 56420-45-2
Catalog number: 56420-45-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Epirubicin, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. It is clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on.
Publictions citing BOC Sciences Products
  • >> More
Pharmorubicin; Ellence
1.Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T1, Kyomori C2, Mizukami T1, Taniyama T1, Izawa N1, Horie Y1, Hirakawa M1, Ogura T1, Nakajima TE1, Tsugawa K3, Boku N1. Mol Clin Oncol. 2016 Apr;4(4):603-606. Epub 2016 Feb 5.
The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.
2.An eco-friendly stability-indicating spectrofluorimetric method for the determination of two anticancer stereoisomer drugs in their pharmaceutical preparations following micellar enhancement: Application to kinetic degradation studies.
El-Kimary EI1, El-Yazbi AF2. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Mar 23;163:145-153. doi: 10.1016/j.saa.2016.03.034. [Epub ahead of print]
A new rapid and highly sensitive stability-indicating spectrofluorimetric method was developed for the determination of two stereoisomers anticancer drugs, doxorubicin (DOX) and epirubicin (EPI) in pure form and in pharmaceutical preparations. The fluorescence spectral behavior of DOX and EPI in a sodium dodecyl sulfate (SDS) micellar system was investigated. It was found that the fluorescence intensity of DOX and EPI in an aqueous solution of phosphate buffer pH4.0 and in the presence of SDS was greatly (about two fold) enhanced and the mechanism of fluorescence enhancement effect of SDS on DOX was also investigated. The fluorescence intensity of DOX or EPI was measured at 553nm after excitation at 497nm. The plots of fluorescence intensity versus concentration were rectilinear over a range of 0.03-2μg/mL for both DOX and EPI with good correlation coefficient (r>0.999). High sensitivity to DOX and EPI was attained using the proposed method with limits of detection of 10 and 9ng/mL and limits of quantitation of 29 and 28ng/mL, for DOX and EPI, respectively.
3.Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L1, Harbeck N2, Singer S3, Eichler M3, Rack B4, Forstbauer H5, Wischnik A6, Scholz C7, Huober J7, Friedl TW7, Weissenbacher T4, Härtl K8, Kiechle M9, Janni W7, Fink V7. Breast. 2016 Apr 4;27:69-77. doi: 10.1016/j.breast.2016.03.003. [Epub ahead of print]
BACKGROUND: The recommendation for adjuvant dose-dense chemotherapy in high risk primary breast cancer is heterogeneous among guidelines. Understanding the impact on QoL is thereby a crucial factor, especially if the benefit is potentially low. This study aims to assess QoL as a secondary outcome in the prospective randomized multi-center ADEBAR trial.
4.Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Möbus V1. Breast Care (Basel). 2016 Feb;11(1):8-12. doi: 10.1159/000444004. Epub 2016 Feb 19.
Meta-analyses persistently confirm the superiority of dose-dense chemotherapy in comparison with standard chemotherapy. In contrast, individual studies have shown conflicting results. These may be explained by different risk profiles of the treated patient populations. Some trials show a significant advantage in disease-free survival (DFS) and overall survival (OS) in the estrogen receptor (ER)-negative population only, whereas trials with high-risk populations like GIM-2 (Gruppo Italiano Mammella) and AGO-iddETC (Arbeitsgemeinschaft Gynäkologische Onkologie, intense dose-dense epirubicin, paclitaxel, and cyclophosphamide) show a significant superiority in DFS and OS for both, ER-negative and ER-positive patients even after 7 and 10 years, respectively, of follow-up. In contrast, the 10-year follow-up data of the E1199/Intergroup trial no longer showed any superiority of weekly paclitaxel for ER-positive/HER2-negative patients; superiority was observed in the triple-negative subgroup only.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Topoisomerase Products

CAS 169869-90-3 Exatecan Mesylate

Exatecan Mesylate
(CAS: 169869-90-3)

Exatecan Mesylate (DX-8951) is a totally synthetic analogue of the topoisomerase I-inhibitor camptothecin, which was synthesised to impart increased aqueous sol...

CAS 519-23-3 Ellipticine

(CAS: 519-23-3)

Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. Ellipticine is also a natural product, isolated in 1959 from the Australian everg...

CAS 57852-57-0 Idarubicin Hydrochloride

Idarubicin Hydrochloride
(CAS: 57852-57-0)

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells wi...

CAS 162706-37-8 Elinafide

(CAS: 162706-37-8)

Elinafide, an isoquinoline derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in anticancer studies.

CAS 57576-44-0 Aclarubicin

(CAS: 57576-44-0)

Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. It intercalates into DNA and inter...

CAS 72496-41-4 Pirarubicin

(CAS: 72496-41-4)

Pirarubicin is an anthracycline antibiotic, and also a DNA/RNA synthesis inhibitor by intercalating into DNA and interacts with topoisomerase II, used as an ant...

CAS 65271-80-9 Mitoxantrone

(CAS: 65271-80-9)

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certai...

NSC 660028
(CAS: 153230-81-0)

NSC 660028, an arylamino etoposide analogue, has been found to be a DNA topoisomerase II inhibitor that was once studied due to its potential anticancer activit...

CAS 78186-34-2 Bisantrene

(CAS: 78186-34-2)

Bisantrene is an anthracenyl bishydrazone used as a particular anticancer drug. Bisantrene can lead to inhibition of DNA replicantion and DNA-protein crosslinki...

CAS 110311-30-3 Amrubicin hydrochloride

Amrubicin hydrochloride
(CAS: 110311-30-3)

Amrubicin hydrochloride is a topoisomerase II inhibitor used in the treatment of lung cancer.

CAS 446-72-0 Genistein

(CAS: 446-72-0)

Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by ...

CAS 529488-28-6 GENZ-644282

(CAS: 529488-28-6)

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibi...

CAS 119413-54-6 Topotecan Hydrochloride

Topotecan Hydrochloride
(CAS: 119413-54-6)

Topocecan is a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes top...

CAS 252979-56-9 Banoxantrone dihydrochloride

Banoxantrone dihydrochloride
(CAS: 252979-56-9)

Banoxantrone dihydrochloride, a bioreductive prodrug, can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor, and ex...

CAS 86639-52-3 SN-38

(CAS: 86639-52-3)

SN-38 is the active metabolite of irinotecan. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN...

CAS 69408-81-7 Amonafide dihydrochloride

Amonafide dihydrochloride
(CAS: 69408-81-7)

Amonafide dihydrochloride is the dihydrochloride salt of amonafide, an imide derivative of naphthalic acid. Amonafide intercalates into DNA and inhibits topoiso...

CAS 211100-13-9 Sabarubicin

(CAS: 211100-13-9)

Sabarubicina, a disaccharide analogue of doxorubicin, is an antineoplastic agent which can intercalate into the DNA of tumor cells and interact with topoisomera...

CAS 33419-42-0 Etoposide

(CAS: 33419-42-0)

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

CAS 136572-09-3 Irinotecan Hydrochloride Trihydrate

Irinotecan Hydrochloride Trihydrate
(CAS: 136572-09-3)

The hydrochloride salt of Irinotecan. Irinotecan is a prodrug that can be activated to 7-ethyl-10-hydroxy-camptothecin (SN-38) by the carboxylesterase-convertin...

CAS 1562066-98-1 Banoxantrone D12 dihydrochloride

Banoxantrone D12 dihydrochloride
(CAS: 1562066-98-1)

The deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a potent topoisomerase II inhibitor.

Chemical Structure

CAS 56420-45-2 Epirubicin

Quick Inquiry

Verification code

Featured Items